Guardant Health acquires Israeli healthtech MetaSight for up to $150M

Guardant Health acquires Israeli healthtech MetaSight for up to $150M
Guardant Health gains amid activist speculation
Guardant Health briefly ticks higher on takeover speculation
Guardant Health rebounds after deciding against buying NeoGenomics
NeoGenomics surges on reports of a potential takeover by Guardant Health
19.1BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US40131M1099
CUSIP
40131M109
Sector
Healthcare
Industry
Diagnostics & Research
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
-1.38
Dividend Share
-
Dividend Yield
-
Earnings Share
-3.6
Wall Street Target Price
173.17
EPS Estimate Current Year
-1.41
EPS Estimate Next Year
-0.40
EPS Estimate Current Quarter
-0.4736
EPS Estimate Next Quarter
-0.3959
Most Recent Quarter
-
Revenue TTM
1,080,215,040
Gross Profit TTM
701,011,968
EBITDA
-408,155,008
Profit Margin
-40.10%
Return On Assets TTM
-17.15%
Return On Equity TTM
-4584.47%
Revenue Per Share TTM
8.491
Qtly Revenue Growth YOY
48.30%
Diluted Eps TTM
-3.6
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
18.7015
Price Book MRQ
55.6696
Enterprise Value Revenue
18
Enterprise Value EBITDA
-5
71.01
1.62%687.76
-2.46%235.02
-1.45%266.51
-1.15%377.31
-0.98%574.26
-0.34%194.98
-0.33%556.62
-0.30%138.37
-0.18%21.55
-0.05%